bermekimab

Home
Ligands
bermekimab

GtoPdb Ligand ID: 8089

Synonyms: MABp1 | RA-18C3 | Xilonix® (proposed trade name)

Comment: Bermekimab (MABp1, Xilonix) is an investigational fully human monoclonal antibody targeting IL-1α, with potential antiinflammatory action. This antibody is the first genuinely human monoclonal antibody to be produced directly from an affinity matured, human immune response. As MABp1 has not been subject to in vitro sequence modification it is predicted to have improved tolerability compared to antibodies that are 'humanised'.
A patent search suggests that Xilonix is the subject of WO2009148575 [3].

No information available.

No information available.

Summary of Clinical Use
MABp1 is in Phase 3 clinical trial as a treatment for refactory colorectal cancer (NCT01021072) and has been granted fast track status by the US FDA to facilitate rapid progression to approval. Phase 1 evaluation for non-small cell lung cancer (NSCLC) is underway.

Summary of Clinical Use

MABp1 is in Phase 3 clinical trial as a treatment for refactory colorectal cancer (NCT01021072) and has been granted fast track status by the US FDA to facilitate rapid progression to approval. Phase 1 evaluation for non-small cell lung cancer (NSCLC) is underway.

Mechanism Of Action and Pharmacodynamic Effects
MABp1 binds specifically to IL-1α, neutralising IL-1α-mediated processes which are related not only to tumour progression (such as cancer-related chronic inflammation, tumour growth and metastasis), but also to cancer-related complications such as weight-loss (cachexia). Blockade of hypothalamic IL-1α activity is believed to normalise metabolic activity thereby correcting the underlying causes of the wasting phenotype associated with malignancy. The rationale for using anti-IL-1α antibodies to treat cancer is discussed further in patent US20100040574 [4].

Mechanism Of Action and Pharmacodynamic Effects

MABp1 binds specifically to IL-1α, neutralising IL-1α-mediated processes which are related not only to tumour progression (such as cancer-related chronic inflammation, tumour growth and metastasis), but also to cancer-related complications such as weight-loss (cachexia). Blockade of hypothalamic IL-1α activity is believed to normalise metabolic activity thereby correcting the underlying causes of the wasting phenotype associated with malignancy. The rationale for using anti-IL-1α antibodies to treat cancer is discussed further in patent US20100040574 [4].